GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>The "invention" descibed in LRG's post suggests altering the fucose in the glycolised end of the ADCC MAb would enhance its activity in ADCC.<

I have no problem with the description of the Chugai patent application posted by LRG. However, enhanced ADCC is not the same thing as enhanced affinity for a mAb’s binding site. To my knowledge, no one is claiming that changing the fucosylation does the latter.


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”